Swedish Orphan Biovitrum Logo

Swedish Orphan Biovitrum

Develops innovative therapies for rare diseases in haematology, immunology, and specialty care.

SOBI | ST

Overview

Corporate Details

ISIN(s):
SE0000872095 (+51 more)
LEI:
549300124Y3MQI87PT35
Country:
Sweden
Address:
Tomtebodavagen 23A, 112 76 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Swedish Orphan Biovitrum (Sobi) is a global biopharmaceutical company dedicated to developing and delivering innovative therapies for people with rare and debilitating diseases. The company focuses its research, development, and commercialization efforts on treatments in the areas of haematology, immunology, and specialty care. Sobi leverages its expertise in protein biochemistry and biologics manufacturing to address significant unmet medical needs. The company is committed to improving patient lives by providing sustainable access to transformative treatments for rare disease communities worldwide.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 137.5 KB
2025-09-30 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 126.9 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
Ändring av antalet aktier och röster i Sobi
Swedish 100.2 KB
2025-08-29 08:00
Declaration of Voting Results & Voting Rights Announcements
New number of shares and votes in Sobi
English 97.9 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi has completed issues of class C shares
English 151.8 KB
2025-08-21 12:35
Share Issue/Capital Change
Sobi har genomfört emissioner av C-aktier
Swedish 151.6 KB
2025-07-16 08:00
Quarterly Report
Swedish 4.1 MB
2025-07-16 08:00
Earnings Release
English 4.1 MB
2025-07-15 19:15
Share Issue/Capital Change
The Board of Directors of Sobi exercises authorisation for repurchase of shares…
English 138.4 KB
2025-07-15 19:15
Transaction in Own Shares
Sobis styrelse utnyttjar återköpsbemyndigande för säkerställande av bolagets åt…
Swedish 137.1 KB
2025-07-01 13:00
M&A Activity
Sobi uppdaterar avtalet med Apellis om royalty på Aspaveli® (systemisk pegcetac…
Swedish 193.0 KB
2025-07-01 13:00
M&A Activity
Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli…
English 202.6 KB
2025-06-28 00:55
Regulatory News Service
FDA approves Gamifant® (emapalumab-lzsg) as first-ever treatment for adults and…
English 227.3 KB
2025-06-28 00:55
Earnings Release
FDA godkänner Gamifant® (emapalumab-lzsg) som den första behandlingen för vuxna…
Swedish 244.4 KB
2025-05-08 11:30
Post-Annual General Meeting Information
Kommuniké från Sobis årsstämma
Swedish 148.7 KB

Automate Your Workflow. Get a real-time feed of all Swedish Orphan Biovitrum filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Swedish Orphan Biovitrum via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-08-30 Katy Mazibuko Other Sell 1,500 480,000.00 SEK
2024-08-30 Katy Mazibuko Other Sell 269 86,012.75 SEK
2024-08-12 Sara Karlsson Other Buy 86 23,391.79 SEK
2024-07-25 Mahmood Ladha Other Buy 84,585 12,360,406.05 SEK
2024-07-23 Mahmood Ladha Other Sell 84,585 24,614,235.00 SEK
2024-06-10 Christin Wesström Other Other 7,433 N/A
2024-06-03 Guido Oelkers Other Buy 117,332 23,965,061.00 SEK
2024-05-30 Guido Oelkers Other Sell 117,332 32,090,302.00 SEK
2024-05-15 Henrik Stenqvist Other Buy 72,534 14,815,069.50 SEK
2024-05-13 Henrik Stenqvist Other Sell 72,534 20,766,484.20 SEK

Peer Companies

Company Country Ticker View
AcuCort AB Logo
Develops a rapid oral film for acute allergies, croup, and chemo-induced nausea.
Sweden ACUC
ADBIOTECH Co.,Ltd. Logo
Develops egg-based IgY antibodies as vaccine/antibiotic alternatives for animal and human health.
South Korea 179530
Advicenne Logo
Develops and commercializes therapies for rare renal diseases for patients of all ages.
France ALDVI
AegirBio AB Logo
Develops user-friendly, saliva-based tests for health monitoring & therapeutic drug monitoring.
Sweden AEGIR
Aelis Farma Logo
Developing novel CB1 receptor inhibitors for treating brain and CNS disorders.
France AELIS
AFC-HD AMS Life Science Co.,Ltd. Logo
An OEM of health foods, supplements, and cosmetics, managing the full value chain from R&D to sales.
Japan 2927
ALK-Abelló Logo
Develops allergy immunotherapy (AIT) and emergency treatments for severe allergies.
Denmark ALK
Alkaloid AD Logo
Manufactures pharmaceuticals, cosmetics, and herbal products for professionals and consumers.
North Macedonia ALK
ALLERGY THERAPEUTICS PLC Logo
Develops innovative, aluminum-free allergy immunotherapy vaccines for the European market.
United Kingdom AGY
Alligator Bioscience Logo
Develops immuno-oncology antibody drugs to activate the immune system against hard-to-treat cancers.
Sweden ATORX

Talk to a Data Expert

Have a question? We'll get back to you promptly.